Mitigating the spread of a virus as infectious as SARS-CoV-2 requires having ample and accurate diagnostic tests available. However, in the United States, community transmission began to occur before adequate testing measures could be implemented.
An area that has been specifically challenging within gastroenterology is the management of how and when to perform GI procedures, especially when many patients with COVID-19 have gastrointestinal (GI) symptoms.
Researchers evaluated the efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders, in patients with moderate to severe ulcerative colitis.
Although patients with COVID-19 are known to present with constitutional and respiratory symptoms such as fever, cough, sore throat, and shortness of breath, there is growing evidence that these patients can also experience significant gastrointestinal symptoms such as nausea, vomiting, and diarrhea.